MEK inhibitor
This page covers all MEK inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting MEK1 and MEK2, MEK, MEK1/2.
Targets
MEK1 and MEK2 · MEK · MEK1/2
Phase 3 pipeline (1)
- Trametinib tablet · West China Hospital · Oncology
Trametinib is a MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes, which are involved in the MAPK/ERK signaling pathway.
Phase 2 pipeline (3)
- ARRY-438162, MEK inhibitor; oral · Array Biopharma, now a wholly owned subsidiary of Pfizer · Oncology
Inhibits MEK, a protein involved in the MAPK/ERK signaling pathway, which is often dysregulated in cancer. - Binimetinib Oral Tablet · Pierre Fabre Medicament · Oncology
MEK1/2 inhibitor - IDE196 · IDEAYA Biosciences · Oncology
Selective inhibitor of MEK1/2
Phase 1 pipeline (7)
- AZD6244 Dosing Period 4 · AstraZeneca · Oncology
AZD6244 is a selective inhibitor of MEK1/2, which are key components of the RAS-RAF-MEK-ERK signaling pathway. - ARRY-300, MEK inhibitor; oral · Array Biopharma, now a wholly owned subsidiary of Pfizer · Oncology
MEK inhibitor - ARRY-142886, MEK inhibitor; oral · Array Biopharma, now a wholly owned subsidiary of Pfizer · Oncology
MEK inhibitor - AZD6244 Dosing Period 1 · AstraZeneca · Oncology
MEK inhibitor - AZD6244 Dosing Period 3 · AstraZeneca · Oncology
MEK inhibitor - ATR-002 MEK Inhibitor · Atriva Therapeutics GmbH · Oncology
MEK inhibitor - AZD6244 Dosing Period 2 · AstraZeneca · Oncology
MEK inhibitor